Clinical trial NCT05346848: Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer
Official title: A Randomized Non-comparative Phase II Multicentric Trial on Short Term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Prostate Cancer
Keywords: unfavorable intermdiate risk prostate cancer
androgen deprivation therapy
radiation therapy
Lead sponsor: Institut Bergonié
Sponsor class: OTHER
Collaborators: name: Bayer
First posted: 2022-04-26
Enrollment: 62
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Randomized non-comparative phase II trial to assess the preliminary signs of antitumor activity of darolutamide plus radiation therapy in patients with unfavorable intermediate risk prostate cancer.

Detailed description: Multicentric randomized non-comparative, open-label, phase II trial, based on signle-stage design, to assess the preliminary signs of antitumor activity of darolutamide plus radiation therapy in patients with unfavorable intermediate risk prostate cancer.

Patients satisfying eligibility criteria will be randomized according to 2 treatment modalities

* Arm A (experimental arm): combination of external beam radiotherapy (EBRT) and 6 months darolutamide.
* Arm B (standard arm): combination of external beam radiotherapy (EBRT) and 6 months ADT (androgen deprivation therapy)

Two patients randomized in arm A for one patient randomized in arm B.

Eligibility criteria: Inclusion Criteria:

1. Age ≥ 18,
2. Histological diagnosis of prostate malignancy cancer
3. Cancer without loco-regional or distant metastasis (tumor assessment must comprise at least Pelvic MRI AND thoraco-abdomino-pelvic contrast-enhanced CT-Scan AND Bone Scintigraphy. (Note that additional assessment by PET-Scan is allowed as per investigator judgement),
4. Unfavorable intermediate risk prostate cancer diagnosis defined by the NCCN Guidelines.

   One of the following criteria is sufficient to define an unfavorable intermediate risk prostate cancer:
   * Gleason = 7 (4+3)
   * ≥ 50% of thecore of biopsies need to be positive for adenocarcinoma

   If these criteria are not being identified, two or three of the following criteria are necessary to define unfavorable intermediate risk prostate cancer:
   * PSA value between 10-20 ng/ml
   * Gleason 7 (3+4) or 6
   * T2b (clinical or radiological) Note: patients with iT3a can be included only if gleason score is 6 and PSA less than 20 .
5. Patients newly diagnosed with an unfavorable intermediate risk prostate cancer according to the protocol criteria or previously diagnosed with low risk (Gleason score \< 6, clinical stage \< T2a, and PSA\< 10) prostate cancer progressing to eligible risk disease according to the protocol criteria within 30 days before registration
6. Patients must have a life expectancy of at least 5 years,
7. Performance status ECOG ≤ 2,
8. Patients without contra-indications to EBRT as per physician judgement,
9. Patients with adequate organ function defined by all the following laboratory values
10. Available archived paraffin-embedded tumor sample for research purpose,
11. Patients with a social security in compliance with the french law,
12. Voluntary signed and dated written informed consent prior to any study specific procedure,
13. Men must agree to use an effective method of contraception throughout the treatment period and for one week after discontinuation of treatment.

Exclusion Criteria:

1. Stage T3b-T4 prostate cancer by clinical examination or radiologic evaluation,
2. Patients with Gleason score ≥8,
3. Patients with PSA \>20 ng/ml,
4. Presence of loco-regional or distant metastasis,
5. Contra-indications to MRI and to contrast-enhanced CT-scan,
6. Hypogonadism or severe androgen deficiency as defined by screening serum testosterone less than 50 ng/dL or below the normal range for the institution.
7. Previous prostate cancer treated by androgen deprivation, chemotherapy, surgery, or radiotherapy,
8. Patients with previous orchiectomy
9. Patients actively receiving or having received within 6 months prior enrollment any concurrent androgens, anti-androgens, estrogens, or progestational agents,
10. Patients having received ketoconazole, finasteride or dutasteride within 30 days of inclusion,
11. Previous and current malignancies other than prostate cancer within the last 5 years with the exception of adequately treated basal cell or squamous cell carcinoma of the skin, acute lymphoblastic leukemia, non-muscle invasive bladder cancer,
12. Severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or uncontrolled infection),
13. History of cerebrovascular accident (within the last 6 months)
14. Impaired cardiac function as defined in the Protocol
15. Uncontrolled hypertension
16. Impairment of gastrointestinal function or GI disease that may significantly alter the absorption of study drug,
17. Major surgery within 4 weeks prior enrolment except pelvic lymph-nodes dissection,
18. Known hypersensitivity to any involved study drug or of its formulation components, to natural gonadotrophin releasing hormone or its analogues
19. Galactose intolerance, total lactase deficiency or glucose-galactose malabsorption syndrome
20. Men who are not using an effective method of contraception as previously described
21. Use of herbal or alternative remedies that may affect hormonal status such as Prostasol or PC-SPES,
22. History of non-compliance to medical regimens or inability to grant consent,
23. Patient unable to follow and comply with the study procedures because of any geographical, social or psychpsychological reasons,
24. Individuals under judicial protection or deprived of liberty.
25. Inability to swallow or to give subcutaneous or intramuscular injections.

Primary outcomes:
measure: Assessment of efficacy in terms of 6-month biological response
timeFrame: 6 months after randomization
Secondary outcomes:
measure: Assessment of efficacy in terms of biological response at the end of darolutamide or ADT
timeFrame: An expected average of 6 months
measure: 2-month biological response
timeFrame: 2 months after randomization
measure: 3-month biological response
timeFrame: 3 months after the end of radiotherapy
measure: 6-month biological response
timeFrame: 6 months after the end of radiotherapy
measure: 9-month biological response
timeFrame: 9 months after the end of radiotherapy
measure: 2-year biological response
timeFrame: 2 years after randomization
measure: 3-year biological response
timeFrame: 3 years after randomization
measure: 5-year biological response
timeFrame: 5 years after randomization
measure: 2-year biochemical progression-free survival (bPFS)
timeFrame: 2 years
measure: 3-year biochemical progression-free survival (bPFS)
timeFrame: 3 years
measure: 5-year biochemical progression-free survival (bPFS)
timeFrame: 5 years
measure: 2-year metastasis free survival (MFS)
timeFrame: 2 years
measure: 3-year metastasis free survival (MFS)
timeFrame: 3 years
measure: 5-year metastasis free survival (MFS)
timeFrame: 5 years
measure: 2-year disease free survival (DFS)
timeFrame: 2 years
measure: 3-year disease free survival (DFS)
timeFrame: 3 years
measure: 5-year disease free survival (DFS)
timeFrame: 5 years
measure: 2-year prostate cancer-specific survival (PCSS)
timeFrame: 2 years
measure: 3-year prostate cancer-specific survival (PCSS)
timeFrame: 3 years
measure: 5-year prostate cancer-specific survival (PCSS)
timeFrame: 5 years
measure: 2-year overall survival (OS)
timeFrame: 2 years
measure: 3-year overall survival (OS)
timeFrame: 3 years
measure: 5-year overall survival (OS)
timeFrame: 5 years
measure: Time to testosterone recovery
timeFrame: An expected average of 6 months
measure: Acute safety profile independently for each treatment strategy
timeFrame: 3 months
measure: Late 2-year safety profile independently for each treatment strategy
timeFrame: 2 years
measure: Late 3-year safety profile independently for each treatment strategy
timeFrame: 3 years
measure: Late 5-year safety profile independently for each treatment strategy
timeFrame: 5 years
measure: Assessment of quality of life
timeFrame: Throughout the follow-up period, an expected average of 5 years
measure: Assessment of erectile dysfunction
timeFrame: Throughout the follow-up period, an expected average of 5 years
measure: Assessment of symptoms of benign prostatic hyperplasia
timeFrame: Throughout the follow-up period, an expected average of 5 years
Other outcomes:
Locations:
city: Avignon
country: France
facility: Sainte Catherine, Institut du Cancer Avignon-Provence
city: Besançon
country: France
facility: CHRU Besançon
city: Bordeaux
country: France
facility: Institut Bergonie
city: Brest
country: France
facility: CHRU Brest - Hôpital Morvan
city: Marseille
country: France
facility: Assitance Publique des Hôpitaux de Marseille - CHU La Timone
city: Paris
country: France
facility: Hôpital de la Pitié Salpétrière
city: Saint-Grégoire
country: France
facility: CHP Saint-Grégoire
city: Saint-Herblain
country: France
facility: Institut de Cancérologie de l'Ouest - Site René Gauducheau
city: Toulouse
country: France
facility: IUCT Oncopôle
city: Toulouse
country: France
facility: Clinique Pasteur
Study officials:
References: